CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Let’s delve into the company’s strengths and weaknesses to gain a better understanding of how to play the stock amid this price surge ... are also using CRISPR technology to address various ...

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $37.77, representing a -0.03% change from its previous close. CRISPR Therapeutics (NasdaqGM:CRSP) witnessed a notable 25% gain ...

BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $80 from $86 and keeps a Buy rating on the shares. While Q1 earnings ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a ...

In the latest trading session, CRISPR ... The stock outperformed the S&P 500, which registered a daily loss of 5.98%. Meanwhile, the Dow experienced a drop of 5.5%, and the technology-dominated ...

Editas Medicine, Inc.’s EDIT share price has dipped by 5.16%, which has investors questioning if this is right time to buy.

We are bullish on CRISPR, giving the stock a strong buy rating and a price target of $70 per share ... rights of the CRISPR-Cas9 gene-editing technology. The legal disputes around the patents ...

In this article, we are going to look at where CRISPR Therapeutics ... Buy rating on the stock. Over the past three months, 20 Wall Street analysts have set a 12-month price target with an average ...

Let’s delve into the company’s strengths and weaknesses to gain a better understanding of how to play the stock amid this price decline ... are also using CRISPR technology to address various ...